You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国生物制药(01177.HK)首季纯利增118.5%至19.14亿元 每股派息2港仙
格隆汇 05-24 17:02

格隆汇5月24日丨中国生物制药(01177.HK)公告,截至2021年3月31日止三个月,集团收入约为72.43亿元(人民币,下同),较去年同期增长约16.4%;毛利约为58.27亿元,同比增长约17.6%;归属于母公司持有者应占盈利约19.14亿元,较去年同期增长约118.5%;归属于母公司持有者的每股基本盈利约10.19分,较去年同期增长约118.7%。派发股息每股2港仙。于2021年3月31日,集团的现金及银行结余约79.32亿元。

期内,新产品销售收入达到约34.34亿元,较去年同期上升约67.0%,占集团总收入约47.3%;抗肿瘤用药销售额约26.38亿元,较去年同期上升约31.8%,占集团收入约36.4%;肝病用药售额约9.46亿元,占集团收入13.1%;心脑血管用药销售额约7.49亿元,占集团收入约10.4%。

集团继续专注肝病、抗肿瘤、呼吸系统和心脑血管等治疗领域的新产品研发。于第一季度内,集团获得临床批件7件、生产批件7件及一致性评价获批12个、申报临床8件、一致性评价申报4个及申报生产2个。已累计有临床批件、正在进行临床试验和申报生产的在研产品共393件,其中肝病用药39件、抗肿瘤用药185件、呼吸系统用药25件、内分泌用药17件、心脑血管用药16件及其它类用药111件。

一直以来,集团十分重视研发,以结合自主创新、联合开发及创仿开发的研发理念,不断提升研发水平和速度,并视其为可持续发展的基础,加大研发的资金投入。截至2021年3月31日止三个月,研发总开支约10.62亿元,占集团收入约14.7%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account